GILD34:BVMF
Gilead Sciences Inc BDR
65,81Â R$
0,00%
(0,00) 1 p
16. okt, 16:56:00 GMT −3 · BRL
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GILD34 põhistatistika genereerimine…
Ava
66,36Â R$
Kõrge
66,41Â R$
Madal
65,81Â R$
Turu kapit.
193,67Â mld
Keskm. maht
261,00
Maht
1,78Â tuh
52 näd kõrgeim
67,38Â R$
52 näd madalaim
51,33Â R$
Käibivad aktsiad
1,24Â mld
Töötajate arv
17Â tuh
Ava
66,36Â R$
Kõrge
66,41Â R$
Madal
65,81Â R$
Turu kapit.
193,67Â mld
Keskm. maht
261,00
Maht
1,78Â tuh
52 näd kõrgeim
67,38Â R$
52 näd madalaim
51,33Â R$
Käibivad aktsiad
1,24Â mld
Töötajate arv
17Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
ad-hoc-news.de
·
1 tunni eest
Gilead Sciences stock sits 2.32 percent below its yearly high
ad-hoc-news.de
·
2 tunni eest
Gilead Sciences stock pre-market at EUR 139.78: biotech group slightly higher
The Motley Fool
·
14 tunni eest
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
Simply Wall Street
·
1 päeva eest
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Profiil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Teave üksuse Gilead Sciences Inc BDR kohta
TegevjuhtDaniel O'Day
Töötajad17 tuh
Asutatud22. juuni 1987
PeakontoridFoster City, California, Ameerika Ãœhendriigid
Sektor-
Veebisaitgilead.com